Search

Your search keyword '"Beelen, Dietrich"' showing total 34 results
Start Over Author "Beelen, Dietrich" Journal bone marrow transplantation
34 results on '"Beelen, Dietrich"'

1. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison

Author

Beelen, Dietrich Wilhelm, primary, Iacobelli, Simona, additional, Koster, Linda, additional, Eikema, Dirk-Jan, additional, van Biezen, Anja, additional, Stölzel, Friedrich, additional, Ciceri, Fabio, additional, Bethge, Wolfgang, additional, Dreger, Peter, additional, Wagner-Drouet, Eva-Maria, additional, Reményi, Péter, additional, Stelljes, Matthias, additional, Markiewicz, Miroslaw, additional, McLornan, Donal P., additional, Yakoub-Agha, Ibrahim, additional, and Mohty, Mohamad, additional

Published
2024
Full Text
View/download PDF

2. Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)

Author

Maffini, Enrico, primary, Labopin, Myriam, additional, Beelen, Dietrich Wilhelm, additional, Kroeger, Nicolaus, additional, Arat, Mutlu, additional, Wilson, Keith M. O., additional, Bay, Jacques-Olivier, additional, Ganser, Arnold, additional, Martin, Hans, additional, Passweg, Jakob, additional, Kottaridis, Panagiotis D., additional, Yakoub-Agha, Ibrahim, additional, Porras, Rocio Parody, additional, Wagner, Eva Maria, additional, Esteve, Jordi, additional, Lanza, Francesco, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2022
Full Text
View/download PDF

3. Total body irradiation + fludarabine compared to busulfan + fludarabine as 'reduced-toxicity conditioning' for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

Author

Giebel, Sebastian, Labopin, Myriam, Sobczyk-Kruszelnicka, Malgorzata, Stelljes, Matthias, Byrne, Jenny, Fegueux, Nathalie, Beelen, Dietrich, Rovira, Montserrat, Spyridonidis, Alexandros, Blaise, Didier, Bornhäuser, Martin, Karadogan, Ihsan, Savani, Bipin, Nagler, Arnon, Mohty, Mohamad, Martin, Sonja, Chevallier, Patrice, Neubauer, Andreas, Damaj, Gandhi, Koc, Yener, Ganser, Arnold, Collin, Matthew, Yakoub-Agha, Ibrahim, Ozdogu, Hakan, Araujo, Mercedes Colorado, Itäla-Remes, Maija, Orchard, Kim, Isaksson, Cecilia, Bethge, Wolfgang, Martin, Hans, Aljurf, Mahmoud, Faber, Edgar, Caballero, Dolores, Zák, Pavel, Leleu, Xavier, Bay, Jacques-Olivier, Rohrlich, Pierre-Simon, Kröger, Nicolaus, Huynh, Anne, Schäfer-Eckart, Kerstin, Milpied, Noel, Lenhoff, Stig, Ho, Aloysius, López, Jose Luis Bello, Mordini, Nicola, Lioure, Bruno, Halaburda, Kazimierz, Olivieri, Attilio, Gedde-Dahl, Tobias, Protheroe, Rachel, Tischer, Johanna, Klammer, Matthias, Clausen, Johannes, Potter, Victoria, Ladetto, Marco, Tilly, Herve, Deconinck, Eric, Brecht, Arne, Müller, Lutz Peter, Heinicke, Thomas, Carrete, Juan Pio Torres, Bazarbachi, Ali, Reményi, Péter, Rubio, Marie Thérèse, Fanin, Renato, Pérez-Simón, Jose Antonio, Niels, Murawski, Diez-Martin, J., Arat, Mutlu, Hermine, Olivier, Socié, Gerard, Cornelissen, Jan, Santarone, Stella, Guyotat, Denis, Bulabois, Claude Eric, Bernasconi, Paolo, Johansson, Jan-Erik, Vrhovac, Radovan, Greinix, Hildegard, Lorenzo, José Luis López, Apte, Shashikant, Craddock, Charles, Kobbe, Guido, Zahrani, Mohsen Al, Dreger, Peter, Lange, Andrzej, Tbakhi, Abdelghani, Meijer, Ellen, Llamas, Carlos Vallejo, Santasusana, Josep Maria Ribera, Corradini, Paolo, Benedetti, Fabio, Rambaldi, Alessandro, Gandemer, Virginie, Malfuson, Jean-Valère, Kaare, Ain, Risitano, Antonio, Petrini, Mario, Selleri, Carmine, Wu, Depei, Hematology, CCA - Cancer Treatment and quality of life, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
medicine.medical_specialty, Transplantation Conditioning, MESH: Busulfan, Medizin, MESH: Graft vs Host Disease, Graft vs Host Disease, [SDV.CAN]Life Sciences [q-bio]/Cancer, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Busulfan, MESH: Hematopoietic Stem Cell Transplantation, MESH: Transplantation Conditioning, Retrospective Studies, Transplantation, Acute leukemia, MESH: Humans, MESH: Middle Aged, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, MESH: Retrospective Studies, Retrospective cohort study, Hematology, Middle Aged, Total body irradiation, Fludarabine, Leukemia, Myeloid, Acute, Regimen, 030220 oncology & carcinogenesis, MESH: Vidarabine, [SDV.IMM]Life Sciences [q-bio]/Immunology, MESH: Leukemia, Myeloid, Acute, business, MESH: Whole-Body Irradiation, Vidarabine, Whole-Body Irradiation, 030215 immunology, medicine.drug
Abstract

International audience; The optimal conditioning for patients with acute myeloid leukemia in first complete remission treated with allogeneic hematopoietic cell transplantation (allo-HCT) has not been defined so far. In this retrospective study, we compared two "reduced-toxicity" regimens: intravenous busulfan at a total dose of 9.6 mg/kg (3 days) + fludarabine (Bu3/Flu) and total body irradiation at a dose of 8 Gy + fludarabine (TBI8Gy/Flu). In the entire study cohort (n = 518), the probabilities of overall survival (OS), leukemia-free survival (LFS), relapse and non-relapse mortality (NRM) at 2 years for Bu3/Flu and TBI8Gy/Flu were 62% vs. 72.5% (p = 0.051), 59.5% vs. 65% (p = 0.15), 30% vs. 20% (p = 0.01), and 10% vs. 14% (p = 0.18), respectively. In multivariate model for patients

Published
2021

4. Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT

Author

Nabergoj, Mitja, primary, Mauff, Katya, additional, Beelen, Dietrich, additional, Ganser, Arnold, additional, Kröger, Nicolaus, additional, Stölzel, Friedrich, additional, Finke, Jürgen, additional, Passweg, Jakob, additional, Cornelissen, Jan, additional, Schub, Natalie, additional, Veelken, Joan Hendrik, additional, Beguin, Yves, additional, Wilson, Keith, additional, Zuckerman, Tsila, additional, Hunault-Berger, Mathilde, additional, Lioure, Bruno, additional, Porras, Rocio Parody, additional, Turlure, Pascal, additional, Kerre, Tessa, additional, Koster, Linda, additional, Hayden, Patrick J., additional, Onida, Francesco, additional, Scheid, Christof, additional, Chalandon, Yves, additional, Robin, Marie, additional, and Yakoub-Agha, Ibrahim, additional

Published
2022
Full Text
View/download PDF

5. Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT

Author

Forcade, Edouard, primary, Chevret, Sylvie, additional, Finke, Jürgen, additional, Ehninger, Gerhard, additional, Ayuk, Francis, additional, Beelen, Dietrich, additional, Koster, Linda, additional, Ganser, Arnold, additional, Volin, Liisa, additional, Sengeloev, Henrik, additional, Michallet, Mauricette, additional, Tischer, Johanna, additional, Jindra, Pavel, additional, Cascon, Maria Jesús Pascual, additional, Koc, Yener, additional, Arat, Mutlu, additional, Tomaszewska, Agnieszka, additional, Hayden, Patrick, additional, de Witte, Theo, additional, Yakoub-Agha, Ibrahim, additional, Kröger, Nicolaus, additional, and Robin, Marie, additional

Published
2022
Full Text
View/download PDF

6. Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

Author

Schetelig, Johannes, primary, Chevallier, Patrice, additional, van Gelder, Michel, additional, Hoek, Jennifer, additional, Hermine, Olivier, additional, Chakraverty, Ronjon, additional, Browne, Paul, additional, Milpied, Noel, additional, Malagola, Michele, additional, Socié, Gerard, additional, Delgado, Julio, additional, Deconinck, Eric, additional, Damaj, Ghandi, additional, Maury, Sebastian, additional, Beelen, Dietrich, additional, Quoc, Stéphanie Nguyen, additional, Shankara, Paneesha, additional, Brecht, Arne, additional, Mayer, Jiri, additional, Hunault-Berger, Mathilde, additional, Bittenbring, Jörg, additional, Thieblemont, Catherine, additional, Lepretre, Stéphane, additional, Baldauf, Henning, additional, de Wreede, Liesbeth C., additional, Tournilhac, Olivier, additional, Yakoub-Agha, Ibrahim, additional, Kröger, Nicolaus, additional, and Dreger, Peter, additional

Published
2021
Full Text
View/download PDF

7. Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT

Author

Peric, Zinaida, primary, Peczynski, Christophe, additional, Polge, Emmanuelle, additional, Kröger, Nicolaus, additional, Sengeloev, Henrik, additional, Radujkovic, Aleksandar, additional, Helbig, Grzegorz, additional, Russell, Nigel, additional, Bunjes, Donald, additional, Socié, Gerard, additional, Potter, Victoria, additional, Beelen, Dietrich, additional, Crawley, Charles, additional, Bloor, Adrian, additional, Finke, Jürgen, additional, Schoemans, Helene, additional, Penack, Olaf, additional, Snowden, John A., additional, Koenecke, Christian, additional, and Basak, Grzegorz W., additional

Published
2021
Full Text
View/download PDF

8. Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party

Author

Hirschbühl, Klaus, primary, Labopin, Myriam, additional, Houhou, Mohamed, additional, Gabellier, Ludovic, additional, Labussière-Wallet, Hélène, additional, Lioure, Bruno, additional, Beelen, Dietrich, additional, Cornelissen, Jan, additional, Wulf, Gerald, additional, Jindra, Pavel, additional, Tilly, Hervé, additional, Passweg, Jakob, additional, Niittyvuopio, Riita, additional, Bug, Gesine, additional, Schmid, Christoph, additional, Nagler, Arnon, additional, Giebel, Sebastian, additional, and Mohty, Mohamad, additional

Published
2020
Full Text
View/download PDF

9. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

Author

Schetelig, Johannes, primary, Chevallier, Patrice, additional, van Gelder, Michel, additional, Hoek, Jennifer, additional, Hermine, Olivier, additional, Chakraverty, Ronjon, additional, Browne, Paul, additional, Milpied, Noel, additional, Malagola, Michele, additional, Socié, Gerard, additional, Delgado, Julio, additional, Deconinck, Eric, additional, Damaj, Ghandi, additional, Maury, Sebastian, additional, Beelen, Dietrich, additional, Quoc, Stéphanie Nguyen, additional, Shankara, Paneesha, additional, Brecht, Arne, additional, Mayer, Jiri, additional, Hunault-Berger, Mathilde, additional, Bittenbring, Jörg, additional, Thieblemont, Catherine, additional, Lepretre, Stéphane, additional, Baldauf, Henning, additional, de Wreede, Liesbeth C., additional, Tournilhac, Olivier, additional, Yakoub-Agha, Ibrahim, additional, Kröger, Nicolaus, additional, and Dreger, Peter, additional

Published
2020
Full Text
View/download PDF

10. Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

Author

Spyridonidis, Alexandros, primary, Labopin, Myriam, additional, Savani, Bipin N., additional, Niittyvuopio, Riitta, additional, Blaise, Didier, additional, Craddock, Charles, additional, Socié, Gerard, additional, Platzbecker, Uwe, additional, Beelen, Dietrich, additional, Milpied, Noel, additional, Cornelissen, Jan J., additional, Ganser, Arnold, additional, Huynh, Anne, additional, Griskevicius, Laimonas, additional, Giebel, Sebastian, additional, Aljurf, Mahmoud, additional, Brissot, Eolia, additional, Malard, Florent, additional, Esteve, Jordi, additional, Peric, Zinaida, additional, Baron, Frédéric, additional, Ruggeri, Annalisa, additional, Schmid, Christoph, additional, Gilleece, Maria, additional, Gorin, Norbert-Claude, additional, Lanza, Francesco, additional, Shouval, Roni, additional, Versluis, Jurjen, additional, Bug, Gesine, additional, Fløisand, Yngvar, additional, Ciceri, Fabio, additional, Sanz, Jamie, additional, Bazarbachi, Ali, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2020
Full Text
View/download PDF

11. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

Author

Spyridonidis, Alexandros, primary, Labopin, Myriam, additional, Savani, Bipin N., additional, Niittyvuopio, Riitta, additional, Blaise, Didier, additional, Craddock, Charles, additional, Socié, Gerard, additional, Platzbecker, Uwe, additional, Beelen, Dietrich, additional, Milpied, Noel, additional, Cornelissen, Jan J., additional, Ganser, Arnold, additional, Huynh, Anne, additional, Griskevicius, Laimonas, additional, Giebel, Sebastian, additional, Aljurf, Mahmoud, additional, Brissot, Eolia, additional, Malard, Florent, additional, Esteve, Jordi, additional, Peric, Zinaida, additional, Baron, Frédéric, additional, Ruggeri, Annalisa, additional, Schmid, Christoph, additional, Gilleece, Maria, additional, Gorin, Norbert-Claude, additional, Lanza, Francesco, additional, Shouval, Roni, additional, Versluis, Jurjen, additional, Bug, Gesine, additional, Fløisand, Yngvar, additional, Ciceri, Fabio, additional, Sanz, Jamie, additional, Bazarbachi, Ali, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2020
Full Text
View/download PDF

12. Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party

Author

Bazarbachi, Abdul Hamid, primary, Al Hamed, Rama, additional, Labopin, Myriam, additional, Afanasyev, Boris, additional, Hamladji, Rose-Marie, additional, Beelen, Dietrich, additional, Eder, Matthias, additional, Scheid, Christof, additional, Wu, Depei, additional, Bunjes, Donald, additional, Stepensky, Polina, additional, Tischer, Johanna, additional, Kröger, Nicolaus, additional, Peric, Zina, additional, Aljurf, Mahmoud, additional, Giebel, Sebastian, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2019
Full Text
View/download PDF

13. EASIX and mortality after allogeneic stem cell transplantation

Author

Luft, Thomas, primary, Benner, Axel, additional, Terzer, Tobias, additional, Jodele, Sonata, additional, Dandoy, Christopher E., additional, Storb, Rainer, additional, Kordelas, Lambros, additional, Beelen, Dietrich, additional, Gooley, Ted, additional, Sandmaier, Brenda M., additional, Sorror, Mohamed, additional, Zeisbrich, Markus, additional, Radujkovic, Aleksandar, additional, Dreger, Peter, additional, and Penack, Olaf, additional

Published
2019
Full Text
View/download PDF

14. Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study

Author

Gatwood, Katie S., primary, Labopin, Myriam, additional, Savani, Bipin N., additional, Finke, Jürgen, additional, Socie, Gerard, additional, Beelen, Dietrich, additional, Yakoub-Agha, Ibrahim, additional, Chevallier, Patrice, additional, Ganser, Arnold, additional, Blaise, Didier, additional, Milpied, Noel, additional, Bruno, Lioure, additional, Mailhol, Audrey, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2019
Full Text
View/download PDF

16. Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT

Author

Battipaglia, Giorgia, primary, Boumendil, Ariane, additional, Labopin, Myriam, additional, Ciceri, Fabio, additional, Tischer, Johanna, additional, Stelljes, Matthias, additional, Ehninger, Gerhard, additional, Beelen, Dietrich, additional, Finke, Jürgen, additional, Van Lint, Maria Teresa, additional, Eder, Matthias, additional, Afanasyev, Boris, additional, Fanin, Renato, additional, Mohty, Mohamad, additional, Ruggeri, Annalisa, additional, and Nagler, Arnon, additional

Published
2019
Full Text
View/download PDF

17. Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party

Author

Hirschbühl, Klaus, Labopin, Myriam, Houhou, Mohamed, Gabellier, Ludovic, Labussière-Wallet, Hélène, Lioure, Bruno, Beelen, Dietrich, Cornelissen, Jan, Wulf, Gerald, Jindra, Pavel, Tilly, Hervé, Passweg, Jakob, Niittyvuopio, Riita, Bug, Gesine, Schmid, Christoph, Nagler, Arnon, Giebel, Sebastian, and Mohty, Mohamad

Abstract

Second- and third-generation tyrosine kinase inhibitors (TKI) play an important role in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). However, data on feasibility and efficacy of using these drugs for persisting or relapsed Ph + ALL after allogeneic stem cell transplantation (alloSCT) are scarce. Based on the EBMT Acute Leukemia Working Party registry, we evaluated the use of second-/third-generation TKI in 140 patients with Ph + ALL, suffering from measurable residual disease (MRD, n= 6), molecular relapse (MRel, n= 23), or hematological relapse (HRel, n= 111) following alloSCT. Treatment included dasatinib in 104, nilotinib in 18, or ponatinib in 18 patients. Forty-nine patients received TKI monotherapy, while 91 received additional treatment. Toxicity of second-/third-generation TKI post alloSCT was comparable to pretransplant use and could be managed with dose reduction or temporary discontinuation. Response rates were 71% (overall) and 61% (following TKI monotherapy). For the entire cohort, 2- and 5-year overall survival (OS) was 49% and 33%, respectively. OS was comparable among patients treated for persisting MRD/MRel and HRel. Among patients treated with TKI monotherapy, 2- and 5-year OS was 38% and 33%, respectively. The data underscore that second-/third-generation TKI are important compounds for the management of active Ph + ALL post alloSCT.

Published
2021
Full Text
View/download PDF

18. Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey

Author

Sellner, Leopold, Schetelig, Johannes, Koster, Linda, Choi, Goda, Blaise, Didier, Beelen, Dietrich, Schianca, Fabrizio Carnevale, Passweg, Jakob, Schanz, Urs, Gyan, Emmanuel, Sora, Federica, Kröger, Nicolaus, Wulf, Gerald. G., Van Gorkom, Gwendolyn, Mayer, Jiri, Orvain, Corentin, Bourhis, Jean Henri, Jindra, Pavel, Potter, Victoria, Zallio, Francesco, Vandenberghe, Elisabeth, Robinson, Stephen, Hayden, Patrick J., Yakoub-Agha, Ibrahim, Montoto, Silvia, and Dreger, Peter

Published
2024
Full Text
View/download PDF

19. Adoptive transfer of cellular immunity against cytomegalovirus by virus-specific lymphocytes from a third-party family donor

Author

Lindemann, Monika, primary, Eiz-Vesper, Britta, additional, Steckel, Nina K., additional, Tischer, Sabine, additional, Fiedler, Melanie, additional, Heinold, Andreas, additional, Klisanin, Vesna, additional, Maecker-Kolhoff, Britta, additional, Blasczyk, Rainer, additional, Horn, Peter A., additional, Beelen, Dietrich W., additional, and Koldehoff, Michael, additional

Published
2018
Full Text
View/download PDF

20. Elevated soluble human leukocyte antigen G levels in patients after allogeneic stem cell transplantation are associated with less severe acute and chronic graft-versus-host disease

Author

Kordelas, Lambros, primary, da Silva Nardi, Fabiola, additional, Wagner, Bettina, additional, Ditschkowski, Markus, additional, Liebregts, Tobias, additional, Lindemann, Monika, additional, Heinemann, Falko M., additional, Horn, Peter A., additional, Beelen, Dietrich W., additional, and Rebmann, Vera, additional

Published
2018
Full Text
View/download PDF

21. Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation

Author

Avivi, Irit, primary, Boumendil, Ariane, additional, Finel, Hervé, additional, Nagler, Arnon, additional, de Sousa, Aïda Botelho, additional, Santasusana, Josep Maria Ribera, additional, Vandenberghe, Elizabeth, additional, Afanasyev, Boris, additional, Bordessoule, Dominique, additional, Moraleda, José Maria, additional, Garcia, Eulogio Conde, additional, Pohlreich, David, additional, Garcia, Gonzalo Gutiérrez, additional, Thomson, Kirsty, additional, Or, Reuven, additional, Beelen, Dietrich, additional, Zuffa, Eliana, additional, Giebel, Sebastian, additional, Berthou, Christian, additional, Salles, Gilles, additional, Melpignano, Angela, additional, Montoto, Silvia, additional, and Dreger, Peter, additional

Published
2018
Full Text
View/download PDF

22. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

Author

Schetelig, Johannes, Chevallier, Patrice, van Gelder, Michel, Hoek, Jennifer, Hermine, Olivier, Chakraverty, Ronjon, Browne, Paul, Milpied, Noel, Malagola, Michele, Socié, Gerard, Delgado, Julio, Deconinck, Eric, Damaj, Ghandi, Maury, Sebastian, Beelen, Dietrich, Quoc, Stéphanie Nguyen, Shankara, Paneesha, Brecht, Arne, Mayer, Jiri, Hunault-Berger, Mathilde, Bittenbring, Jörg, Thieblemont, Catherine, Lepretre, Stéphane, Baldauf, Henning, de Wreede, Liesbeth C., Tournilhac, Olivier, Yakoub-Agha, Ibrahim, Kröger, Nicolaus, and Dreger, Peter

Abstract

No studies have been reported so far on bridging treatment with idelalisib for patients with chronic lymphocytic leukemia (CLL) prior to allogeneic hematopoietic cell transplantation (alloHCT). To study potential carry-over effects of idelalisib and to assess the impact of pathway-inhibitor (PI) failure we performed a retrospective EBMT registry-based study. Patients with CLL who had a history of idelalisib treatment and received a first alloHCT between 2015 and 2017 were eligible. Data on 72 patients (median age 58 years) were analyzed. Forty percent of patients had TP53mut/delCLL and 64% had failed on at least one PI. No primary graft failure occurred. Cumulative incidences of acute GVHD °II–IV and chronic GVHD were 51% and 39%, respectively. Estimates for 2-year overall survival (OS), progression-free survival (PFS), and cumulative incidences of relapse/progression (CIR) and non-relapse mortality NRM were 59%, 44%, 25%, and 31%. In univariate analysis, drug sensitivity was a strong risk factor. For patients who had failed neither PI treatment nor chemoimmunotherapy (CIT) the corresponding 2-year estimates were 73%, 65%, 15%, and 20%, respectively. In conclusion, idelalisib may be considered as an option for bridging therapy prior to alloHCT. Owing to the high risk for acute GVHD intensified clinical monitoring is warranted.

Published
2021
Full Text
View/download PDF

23. Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT

Author

Waidhauser, Johanna, Labopin, Myriam, Esteve, Jordi, Kröger, Nicolaus, Cornelissen, Jan, Gedde-Dahl, Tobias, Van Gorkom, Gwendolyn, Finke, Jürgen, Rovira, Montserrat, Schaap, Nicolaas, Petersen, Eefke, Beelen, Dietrich, Bunjes, Donald, Savani, Bipin, Schmid, Christoph, Nagler, Arnon, and Mohty, Mohamad

Abstract

Acute myeloid leukemia with runt-related transcription factor 1 gene mutation (RUNX1+ AML) is associated with inferior response rates and outcome after conventional chemotherapy. We performed a retrospective, registry-based analysis to elucidate the prognostic value of RUNX1mutation after allogeneic stem cell transplantation (alloSCT). All consecutive adults undergoing alloSCT for AML in first complete remission (CR1) between 2013 and 2019 with complete information on conventional cytogenetics and RUNX1mutational status were included. Endpoints of interest were cumulative relapse incidence, non-relapse mortality, overall and leukemia-free survival (OS/LFS), and GvHD-free/relapse-free survival. A total of 674 patients (183 RUNX1+, 491 RUNX1−) were identified, with >85% presenting as de novoAML. Median follow-up was 16.4 (RUNX1+) and 21.9 (RUNX1−) months. Survival rates showed no difference between RUNX1+ and RUNX1− patients either in univariate or multivariate analysis (2-year OS: 67.7 vs. 66.1%, p= 0.7; 2-year LFS: 61.1 vs. 60.8%, p= 0.62). Multivariate analysis identified age, donor type and poor cytogenetics as risk factors for inferior outcome. Among patients with RUNX+AML, older age, reduced intensity conditioning and minimal residual disease at alloSCT predicted inferior outcome. Our data provide evidence that the negative influence of RUNX1mutations in patients with AML can be overcome by transplantation in CR1.

Published
2021
Full Text
View/download PDF

24. Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey

Author

Sellner, Leopold, Schetelig, Johannes, Koster, Linda, Choi, Goda, Blaise, Didier, Beelen, Dietrich, Schianca, Fabrizio Carnevale, Passweg, Jakob, Schanz, Urs, Gyan, Emmanuel, Sora, Federica, Kröger, Nicolaus, Wulf, Gerald. G., Van Gorkom, Gwendolyn, Mayer, Jiri, Orvain, Corentin, Bourhis, Jean Henri, Jindra, Pavel, Potter, Victoria, Zallio, Francesco, Vandenberghe, Elisabeth, Robinson, Stephen, Hayden, Patrick J., Yakoub-Agha, Ibrahim, Montoto, Silvia, and Dreger, Peter

Published
2020
Full Text
View/download PDF

25. Frequency of lethal central nervous system neurotoxicity in patients undergoing allogeneic stem cell transplantation: a retrospective registry analysis

Author

Schultze-Florey, Christian R., Peczynski, Christophe, de Marino, Ivan, Polge, Emmanuelle, Socié, Gerard, Blaise, Didier, Beelen, Dietrich, Franke, Georg-Nicolaus, Kröger, Nicolaus, Stelljes, Matthias, Afanasyev, Boris, Potter, Victoria, Gerbitz, Armin, Schetelig, Johannes, Peric, Zinaida, Schoemans, Hélène, Koenecke, Christian, and Basak, Grzegorz W.

Published
2020
Full Text
View/download PDF

26. EASIX and mortality after allogeneic stem cell transplantation

Author

Luft, Thomas, Benner, Axel, Terzer, Tobias, Jodele, Sonata, Dandoy, Christopher E., Storb, Rainer, Kordelas, Lambros, Beelen, Dietrich, Gooley, Ted, Sandmaier, Brenda M., Sorror, Mohamed, Zeisbrich, Markus, Radujkovic, Aleksandar, Dreger, Peter, and Penack, Olaf

Abstract

Allogeneic stem cell transplantation (alloSCT) is an effective immunotherapy in patients with hematological malignancies. Endothelial dysfunction was linked to major complications after alloSCT. We asked the question if the “Endothelial Activation and Stress Index” (EASIX; [(creatinine × LDH) ÷ thrombocytes]) can predict mortality after alloSCT. We performed a retrospective cohort analysis in five alloSCT centers in the USA and Germany. EASIX was assessed prior to conditioning (EASIX-pre) and correlated with mortality in 755 patients of a training cohort in multivariable models. The predictive model established in the training cohort was validated in 1267 adult allo-recipients. Increasing EASIX-pre predicted lower overall survival (OS) after alloSCT, and successful model validation was achieved for the validation cohort. We found that EASIX-pre predicts OS irrespective of established scores. Moreover, EASIX-pre was also a significant prognostic factor for transplant-associated microangiopathy. Finally, EASIX-pre correlated with biomarkers of endothelial homeostasis such as CXCL8, interleukin-18, and insulin-like-growth-factor-1 serum levels. This study establishes EASIX-pre based on a standard laboratory biomarker panel as a predictor of individual risk of mortality after alloSCT independently from established clinical criteria.

Published
2020
Full Text
View/download PDF

27. Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party

Author

Bazarbachi, Abdul Hamid, Al Hamed, Rama, Labopin, Myriam, Afanasyev, Boris, Hamladji, Rose-Marie, Beelen, Dietrich, Eder, Matthias, Scheid, Christof, Wu, Depei, Bunjes, Donald, Stepensky, Polina, Tischer, Johanna, Kröger, Nicolaus, Peric, Zina, Aljurf, Mahmoud, Giebel, Sebastian, Nagler, Arnon, and Mohty, Mohamad

Abstract

Treatment of relapsed/refractory acute lymphoblastic leukemia (RR-ALL) remains a clinical challenge with generally dismal prognosis. Allogeneic stem-cell transplantation using sequential conditioning (“FLAMSA”-like) has shown promising results in relapsed/refractory acute myeloid leukemia, but little is known about its efficacy in RR-ALL. We identified 115 patients (19–66 years) with relapsed (74%) or primary-refractory (26%) ALL allografted from matched related (31%), matched unrelated (58%), or haploidentical donor (11%). Median follow-up was 37 (13–111) months. At day 100, cumulative incidences of grade II–IV/III–IV acute graft-versus-host-disease (GVHD) were 30% and 17%, respectively. Two-year cumulative incidence of chronic GVHD was 25% with 11% extensive cases. Two-year relapse incidence (RI) was 45%, non-relapse mortality was 41%. Two-year leukemia free survival (LFS) was 14%, overall survival (OS) 17%, and GVHD relapse-free survival (GRFS) was 14%. In multivariable analysis, Karnofsky score <90 negatively affected RI, LFS, OS, and GRFS. Conditioning with chemotherapy alone, compared with total body irradiation (TBI) negatively affected RI (HR = 3.3; p= 0.008), LFS (HR = 1.94; p= 0.03), and OS (HR = 2.0; p= 0.03). These patients still face extremely poor outcomes, highlighting the importance of incorporating novel therapies (e.g., BITE antibodies, inotuzumab, CAR-T cells). Nevertheless, patients with RR-T-cell ALL remain with an unmet treatment need, for which TBI-based sequential conditioning could be one of few available options.

Published
2020
Full Text
View/download PDF

28. Allogeneic transplantation of peripheral blood stem cell grafts results in a massive decrease of primitive hematopoietic progenitor frequencies in reconstituted bone marrows

Author

Kordelas, Lambros, Görgens, André, Radtke, Stefan, Horn, Peter A., Beelen, Dietrich W., and Giebel, Bernd

Abstract

The success of allogeneic hematopoietic stem cell transplantation (alloSCT) is indicated by the reconstitution of the peripheral blood system of patients after alloSCT and the engraftment of hematopoietic stem and progenitor cells (HSPCs) into their bone marrow (BM). The number of CD34+cells is commonly used as surrogate for the content of hematopoietic stem cells in the grafts. During the last decade, several antigens (including CD133, CD45RA, CD38, and CD10) were identified allowing discrimination of different HSPC subpopulations within the human CD34+cell compartment. Although such studies increased our understanding of early human hematopoiesis tremendously, hardly any study dissected the CD34+compartment in the alloSCT setting. Consequently, we comprehensively analyzed the CD34+compartment in G-CSF-stimulated peripheral blood stem cell grafts of allogeneic donors, in BM samples of the respective recipients 4 weeks after alloSCT, and in BM samples of healthy donors. We demonstrate that alloSCT is associated with a dramatic shift from primitive to more mature HSPC types. Upon investigating whether the composition of engrafted CD34+cells has any impact on the incidence and severity of graft-versus-host disease, we did not find any correlation. However, more detailed analyses of the CD34+compartment may elucidate associations with other transplantation-related complications.

Published
2020
Full Text
View/download PDF

29. Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study

Author

Gatwood, Katie S., Labopin, Myriam, Savani, Bipin N., Finke, Jürgen, Socie, Gerard, Beelen, Dietrich, Yakoub-Agha, Ibrahim, Chevallier, Patrice, Ganser, Arnold, Blaise, Didier, Milpied, Noel, Bruno, Lioure, Mailhol, Audrey, Mohty, Mohamad, and Nagler, Arnon

Abstract

Allogeneic hematopoietic cell transplant (HCT) is a curative therapy for patients with secondary acute myeloid leukemia (sAML), though the impact of conditioning regimens on HCT outcomes for patients with antecedent lymphoid malignancy is largely unknown. This multicenter, retrospective registry study of the ALWP of the EBMT assessed HCT outcomes in this population. In all, 549 patients ≥18 years with sAML following an antecedent lymphoid malignancy treated with first allograft between 2000–2016 were included. Myeloablative (MAC) and reduced intensity conditioning (RIC) was given in 258 (47%) and 291 (53%), respectively. At 2 years, leukemia-free survival (LFS) was 31.7% (95% CI, 27.5–35.9), overall survival (OS) was 37.4% (95% CI, 33–41.8), nonrelapse mortality (NRM) was 28.9% (95% CI, 25–33), and GVHD-free, relapse-free survival (GRFS) was 22.8% (95% CI, 19–26.6). In multivariate analysis, patients receiving RIC regimens had lower risk of NRM (HR: 0.58, CI: 0.40–0.83, p= 0.003), and improved LFS (HR: 0.67, CI: 0.52–0.85, p= 0.001). Patients with prior autologous HCT had inferior LFS (HR: 1.30, CI: 1.01–1.67, p= 0.01). This study demonstrates that sAML patients following prior lymphoid malignancy treated with RIC regimens have a lower risk of NRM and improved LFS, OS, and GFRS. Other variables associated with inferior outcomes include older age, active disease, adverse cytogenetics, and prior auto-HCT.

Published
2020
Full Text
View/download PDF

31. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT

Author

Gorkom, Gwendolyn, Gelder, Michel, Eikema, Dirk-Jan, Blok, Henric-Jan, Lint, M., Koc, Yener, Ciceri, Fabio, Beelen, Dietrich, Chevallier, Patrice, Selleslag, Dominik, Blaise, Didier, Foá, Roberto, Corradini, Paolo, Castagna, Luca, Moreno, Carol, Solano, Carlos, Müller, Lutz Peter, Tischer, Johanna, Hilgendorf, Inken, Hallek, Michael, Bittenbring, Jörg, Theobald, Matthias, Schetelig, Johannes, and Kröger, Nicolaus

Abstract

Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.

Published
2018
Full Text
View/download PDF

32. Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

Author

Schetelig, Johannes, Chevallier, Patrice, van Gelder, Michel, Hoek, Jennifer, Hermine, Olivier, Chakraverty, Ronjon, Browne, Paul, Milpied, Noel, Malagola, Michele, Socié, Gerard, Delgado, Julio, Deconinck, Eric, Damaj, Ghandi, Maury, Sebastian, Beelen, Dietrich, Quoc, Stéphanie Nguyen, Shankara, Paneesha, Brecht, Arne, Mayer, Jiri, Hunault-Berger, Mathilde, Bittenbring, Jörg, Thieblemont, Catherine, Lepretre, Stéphane, Baldauf, Henning, de Wreede, Liesbeth C., Tournilhac, Olivier, Yakoub-Agha, Ibrahim, Kröger, Nicolaus, and Dreger, Peter

Published
2022
Full Text
View/download PDF

34. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT.

Author

van Gorkom G, van Gelder M, Eikema DJ, Blok HJ, van Lint MT, Koc Y, Ciceri F, Beelen D, Chevallier P, Selleslag D, Blaise D, Foá R, Corradini P, Castagna L, Moreno C, Solano C, Müller LP, Tischer J, Hilgendorf I, Hallek M, Bittenbring J, Theobald M, Schetelig J, and Kröger N

Subjects
Adult, Aged, Cyclophosphamide therapeutic use, Female, Graft vs Host Disease prevention & control, Hematopoietic Stem Cell Transplantation mortality, Humans, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Male, Middle Aged, Retrospective Studies, Survival Analysis, Treatment Outcome, Hematopoietic Stem Cell Transplantation methods, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Transplantation, Haploidentical mortality
Abstract

Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results